Eli Lilly and Company has revealed a $1 billion expansion at its Limerick, Ireland manufacturing site to boost production of biologic ingredients for its Alzheimer's treatments. Additionally, the company has introduced an $800 million expansion at its Kinsale, Ireland facility, which started producing medications last year to address the demand for Lilly's diabetes and obesity treatments.

The additional investment is part of the most ambitious manufacturing expansion agenda in the company’s history. Since 2020, Lilly has committed more than $20 billion to build, expand and acquire manufacturing facilities in the U.S. and Europe.

-- Advertisement --

The project is supported by the Irish Government through IDA Ireland.

Minister for Enterprise Trade & Employment Peter Burke TD said: "This marks two fantastic investments from Eli Lilly and Company - both the announcement of a $1 billion expansion of Lilly’s Limerick site in Raheen and the unveiling of the new $800 million facility expansion in Kinsale. These state-of-the-art facilities will contribute to the treatment of diseases affecting millions of people across the world. They will also create hundreds of new jobs, directly and indirectly, adding to the thousands already employed in Ireland by Lilly. Eli Lilly and Company has made a huge commitment to Ireland for almost half a century and these announcements today further solidify their confidence in Ireland as a global leader in the Biopharma sector. Thanks to the Lilly team for their continued investment in Ireland, which is greatly valued by the Irish Government, and I look forward to future collaboration over the next half a century, alongside our IDA colleagues."